Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead - LARVOL DELTA

Early Access Program in oncology: Retrospective study at a Portuguese hospital (ECOP 2024) - "During the study period were submitted 163 EAP requests for abiraterone, amivantamab, bevacizumab, durvalumab, encorafenib, enfortumab, everolimus, erdafitinib, lenvatinib, lurbinectedin, niraparib, nivolumab, olaparib, pembrolizumab, pertuzumab, ramucirumab, sacituzumab govitecan, selpercatinib, trifluridine/tipiracil, trametinib+dabrafenib, trastuzumab-deruxtecan and tucatinib. Conclusion Most cases correspond to metastatic disease, EAPs facilitate timely access to innovative therapies for patients with high unmet medical needs. The majority of situations were financed, which confirms the importance of EAPs in an era where oncology is constantly innovating."

Retrospective data • Gastrointestinal Disorder • Oncology

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan. (PubMed, Int J Clin Oncol) - No abstract available

Japanese regulatory • Journal • Biliary Cancer • Biliary Tract Cancer • Brain Cancer • Breast Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Glioma • Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review. (PubMed, Curr Neurol Neurosci Rep) - "In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases...Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized,..."

IO biomarker • Journal • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • EGFR • HER-2

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma (OncLive) - P3 | N=696 | TROPiCS-04 (NCT04527991) | Sponsor: Gilead Sciences | "The median OS with the antibody-drug conjugate (ADC; n = 355) was 10.3 months (95% CI, 9.1-11.8) vs 9.0 months (95% CI, 7.5-9.7) with physician’s choice of chemotherapy (n = 356; HR, 0.86; 95% CI, 0.73-1.02; P = .087), missing the study’s primary end point. The OS rates in the respective arms at 12 months were 44% (95% CI, 39%-49%) and 37% (95% CI, 32%-42%). The hazard ratios of OS consistently favored sacituzumab govitecan over chemotherapy in the majority of prespecified subgroups. Moreover, the median PFS with sacituzumab govitecan was 4.2 months (95% CI, 3.8-4.5) vs 3.6 months (95% CI, 2.9-4.2) with chemotherapy (HR, 0.86; 95% CI, 0.72-1.03). The 12-month PFS rate in the ADC arm was 14.5% (95% CI, 10%-19%) vs 9% (95% CI, 5%-14%) in the chemotherapy arm."

P3 data • Urothelial Cancer

Real-world data on the use of trastuzumab deruxtecan in breast cancer patients at a tertiary hospital in Ourense, Spain. (SABCS 2024) - "Ehertu was administered most frequently in the thrid line of treatment or later in 63% of cases; 42% had previously received another ADC (TDM-1, sacituzumab govitecan, etc)...7 patients were Her2+++ patients from the debut, and 6 patients were treated in the indication of Her2 low (Her2 1+,2++/ISH-) 100% of Her2 +++ patients initially received a pertuzumab+trastuzumab+taxane regimen (Cleopata regimen)... These data undeline the effectiveness of trastuzumab deruxtecan in a heterogeneous and highly pretreated population. More follow-up is required to evaluated the impact on overwall survival, but preliminary results indicate that it is an effective treatment with tolerable toxicity in a high percentage of patients with advanced breast cancer. This drug should be considered in all who present any percentage positivity (measured by immunohistochemistry) in Her 2."

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer. (PubMed, Clin Med Insights Oncol) - "Today, novel agents called antibody drug conjugates (ADCs), including enfortumab vedotin (EV) and sacituzumab govitecan (SG), have been approved for la/mUC offering patients treatment options following or instead of traditional chemotherapy...In 2023, EV in combination with pembrolizumab almost doubled progression-free and overall survival versus platinum-based chemotherapy, which led to accelerated FDA approval as first-line treatment for all patients with la/mUC...Finally, a recent cancer agnostic accelerated approval for trastuzumab deruxtecan (T-DXd) in HER2-positive (IHC3+) solid tumors provides another active ADC option for biomarker-selected patients with treatment refractory la/mUC. Several new ADCs are being investigated in urothelial cancer (UC) clinical trials. This review summarizes the clinical studies and real-world data regarding the use of ADCs in UC."

Journal • Metastases • Review • Bladder Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Disorders • Neutropenia • Oncology • Pain • Solid Tumor • Urothelial Cancer • HER-2

Survival Outcomes of Sequential Topoisomerase I Antibody-Drug Conjugate Therapies in Metastatic Breast Cancer Patients (SABCS 2024) - "Background: Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are ADCs with topoisomerase 1 payloads targeting HER2 and TROP2, respectively, that are approved for use in metastatic breast cancers (MBC). Our analysis indicates no clear survival differences between SG followed by T- DXd vs T-DXd followed by SG and whether these ADCs were used sequentially or nonsequentially. Further studies with rational biomarker analyses with larger sample sizes is warranted to draw more definitive conclusions."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • TOP1

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Businesswire) - "Gilead Sciences, Inc...today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy...The Breakthrough Therapy Designation is based on results from the global Phase 2 TROPiCS-03 study ES-SCLC cohort, which showed encouraging results....These data support further investigation of Trodelvy in ES-SCLC and Gilead plans to initiate a Phase 3 clinical trial in this patient population."

Breakthrough therapy • New P3 trial • Small Cell Lung Cancer

Predictive Factors of Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review. (PubMed, Cancers (Basel)) - "This narrative review explores key predictive factors influencing the efficacy of ADCs, focusing on HER2-targeted therapies, such as trastuzumab emtansine and trastuzumab deruxtecan, as well as sacituzumab govitecan for triple-negative breast cancer. Finally, future perspectives on the sequential use of ADCs and potential combination therapies are highlighted, along with emerging agents targeting alternative antigens like HER3 and LIV-1. Overall, identifying predictive biomarkers and overcoming resistance mechanisms are essential for optimizing the use of ADCs in metastatic breast cancer, thereby improving patient outcomes."

Biomarker • Journal • Metastases • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ERBB3 • TACSTD2

Long term survival in patient with metastatic breast cancer treated with sacituzmab govitecan. (PubMed, Recenti Prog Med) - "The clinical case presented refers to a woman suffering from metastatic breast cancer treated with sacituzumab govitecan (SG) who has a long progression-free survival. The case is characterized by the extreme aggressiveness of the neoplastic disease that relapses during adjuvant hormonal treatment with a metastatic disease that presents immunohistochemical characteristics different from the primary tumor. After first-line therapy with nabpaclitaxel and atezolizumab and the subsequent one with carboplatin and gemcitabine, both characterized by short PFS, the third line with SG is characterized by obtaining a complete response and a prolonged PFS as well as extreme tolerability that continues to this day after 15 months of treatment."

Journal • Metastases • Breast Cancer • Oncology • Solid Tumor

Real-World Efficacy of Fam-Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer (SABCS 2024) - "Eleven percent of patients had received prior sacituzumab govitecan. This RW analysis shows that T-DXd is prescribed to a more heavily pre-treated population. The rwPFS of 6.8 months in patients with HER2-low breast cancer treated with T-DXd is lower than expected and may be due to the more pre-treated population."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

Multi-Site Real World Data of Patient Reported Outcomes from Patients with Breast Cancer on Immunotherapy or Antibody Drug Conjugates using the Carevive PROMPT™ Web-Based Platform (SABCS 2024) - "Descriptive statistics are shared from 97 patients with breast cancer who were treated with immunotherapy (atezolizumab, pembrolizumab) and/or an antibody drug conjugate (ado-trastuzumab emtansine (T-DM1), fam-trastuzumab deruxtecan-nxki (T-Dxd), sacituzumab govitecanhziy (sacituzumab)) as standard of care. However, a limitation is that although the questionnaires were sufficient to alert clinical care teams of potential toxicity in general, they were not specific to toxicities associated with immunotherapies or antibody drug conjugates. Therefore, an opportunity area for the field is to create more specific or tailored PROs for immune toxicities associated with immunotherapies, antibody drug conjugates, and cell-based therapies."

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

A case of sequential alpelisib and capivasertib in a patient with metastatic breast cancer harboring both a PIK3CA and AKT mutations (SABCS 2024) - "Therapies targeting mutations in this pathway approved in conjunction with endocrine therapy include alpelisib, everolimus and capivasertib...She received nab-paclitaxel/atezolizumab for 4 months, letrozole and abemaciclib for 2 months, letrozole alone for 6 months, and letrozole and ribociclib for 6 weeks. Given presence of PIK3CA mutation, 4th line treatment with fulvestrant and alpelisib was planned...After progressing on capecitabine after 2 months, alpelisib with exemestane was initiated...Due to a low ejection fraction despite work with cardiooncology, she was not a candidate for trastuzumab deruxtecan. She progressed on oral cyclophosphamide and methotrexate after 2 months and Sacituzumab govitecan after 3 months...Comprehensive biomarker assessment is needed to identify patients who may benefit from sequential therapies. There is a need for trials comparing therapies that target the PI3K pathway at distinct points, potential sequencing of these therapies, and the..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR • PIK3CA

Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC) – retrospective study from the nationwide Flatiron database (SABCS 2024) - "Among patients with HER2+ MBC, the most commonly administered post-T-DXd regimens and median rwPFS were: tucatinib, trastuzumab and capecitabine (n=95, 27.0%) with a rwPFS of 4.7 mo; endocrine treatment (ET)-based regimens (n=57, 16.2%) with a rwPFS of 4.4 mo; chemotherapy + anti-HER2 antibodies (n=56, 15.9%), with a rwPFS of 5.0 mo; anti-HER2 antibodies +/- tyrosine kinase inhibitors (n=34, 9.7%), with a rwPFS of 7.3 mo; TDM1 (n=27, 7.7%), with a rwPFS of 4.1 mo; and sacituzumab govitecan (SG, n=16, 4.6%), with a rwPFS of 2.3 mo. Among patients with HR+/HER2- MBC, the most commonly administered post-T-DXd regimens and median rwPFS were: SG (n=66, 29.7%) with a rwPFS of 2.5 mo; ET-based regimens (n=46, 20.7%) with a rwPFS of 3.2 mo; taxanes (n=20, 9.0%), with a rwPFS of 3.8 mo; capecitabine (n=18, 8.1%), with a rwPFS of 5.8 mo; and eribulin (n=16, 7.2%), with a rwPFS of 5.9 mo... In a large real-world database, outcomes of post-T-DXd treatments significantly differed by..."

Metastases • Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Breast Cancer • Oncology • Solid Tumor

SERIES: SEquencing Sacituzumab Govitecan (SG) AfteR Trastuzumab Deruxtecan (T-DXd) In ER+/HER2 LOW MetaStatic Breast Cancer (SABCS 2024) - P2 | "Secondary endpoints include clinical benefit rate, progression free survival, overall survival, duration of response, global quality of life, and adverse events. The trial is currently enrolling patients (NCT06263543)."

Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort. (PubMed, Mol Diagn Ther) - "Our data indicate that targeted therapy using e.g., trastuzumab deruxtecan, bicalutamide, pembrolizumab, cetuximab, entrectinib or sacituzumab govitecan might be a promising option especially for a relevant subset of patients with RM-SGC not suitable for salvage surgery. However, evidence from clinical studies regarding response rates to these therapies remains sparse, which underlines the need of multicenter clinical trials."

IO biomarker • Journal • Oncology • Salivary Gland Cancer • AR • EGFR • HER-2 • NTRK • NTRK1 • NTRK2 • NTRK3 • TACSTD2

Transparency for patient assistance and compassionate use programs for high-cost intravenous and oral therapies in breast cancer patients at an NCI-designated cancer center (SABCS 2024) - "The OAMs and high-cost IV therapies of interest include palbociclib, ribociclib, abemaciclib, famtrastuzumab deruxtecan, trastuzumab, pertuzumab, pembrolizumab, goserelin, leuprolide, liposomal doxorubicin, and sacituzumab govitecan. Mitigation of financial toxicity should include transparency and metrics for time to drug approval for patients. Our review showed that the median time to patient assistance approval for OAMs and high-cost IV therapies was 19 and 17 days, respectively, and this can be in addition to the time to initial insurance denial or determination. This review also identifies patients with Medicare as a population that may benefit from upfront financial navigation to expedite paperwork around the drug approval and acquisition process, as their median copay was $2520."

Clinical • Breast Cancer • Oncology • Solid Tumor

Incidence of antibody-drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis. (PubMed, Ther Adv Drug Saf) - "Sacituzumab govitecan caused the highest incidence of all grades of alanine aminotransferase (ALT) elevation at 25.30% (95% confidence interval (CI): 19.29-31.82). Trastuzumab deruxtecan caused the highest incidence of all grades of aspartate aminotransferase (AST) elevation...Conversely, trastuzumab emtansine caused the highest incidence of grade ⩾3 AST and ALT elevation (incidence rates were 3.95% (95% CI: 2.39-5.85) and 3.42% (95% CI: 1.95-5.24), respectively). Hepatotoxicity is an adverse reaction that cannot be ignored when ADCs are used for treating breast cancer. Moreover, clinicians should pay more attention to the assessment of patients' liver function and monitoring of liver indices, particularly ALT and AST, when using ADCs."

Journal • Retrospective data • Review • Breast Cancer • Hepatology • Oncology • Solid Tumor

Exploring Treatment Options Following Progression to CDK4/6 Inhibitor in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis (SABCS 2024) - "Specifically, 9 studies included biological agnostic therapy (CDK4/6i, mTOR inhibitors, immunotherapy), 7 novel ET (including selective estrogen receptor degraders – oral SERD), 5 targeted therapies (PI3K, AKT and PARP inhibitors), 3 antibody-drug conjugates (ADCs: trastuzumab deruxtecan [T-DXd] and sacituzumab govitecan), and 2 CT (eribulin, VEX metronomic). Control arms consisted of either ET alone (mainly fulvestrant) or standard CT (paclitaxel, capecitabine, eribulin, gemcitabine, or vinorelbine)...Among all therapies, TDXd showed the largest PFS benefit compared to standard CT [HR 0.51 (CI: 0.45 – 0.57)], followed by ribociclib plus ET compared to ET alone [HR 0.57 (CI: 0.45 – 0.72)]...Biological agnostic therapies offer some survival improvement but at the cost of increased toxicity as compared to other options. These findings could help tailor the most suitable treatment for each patient, determining the optimal sequence following progression to CDK4/6i for..."

Metastases • Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

The impact of ethnicity on benefit from novel drugs approved for breast cancer treatment: a systematic review and meta-analysis of randomized phase 3 trials of the last decade. (SABCS 2024) - "23 phase III RCTs were identified in the aBC setting, with 1547 (11.1%) patients of Asian ethnicity. Experimental drugs tested included CDK4/6i (palbociclib, ribociclib, abemaciclib), SERD (elacestrant), PI3Ki (alpelisib), PARPi (olaparib, talazoparib), broad variety of anti-HER2 drugs (tucatinib, trastuzumab deruxtecan, pertuzumab, T-DM1, neratinib, margetuximab), anti-PD-1 and anti-PD-L1 drugs (pembrolizumab, atezolizumab) and anti-TROP2 drug (sacituzumab govitecan). 16 RCTs provided HR (95%CI) for PFS in the subgroup of Asians and 17 RCTs for Non-Asians."

IO biomarker • P3 data • Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Integration of Novel Antibody–Drug Conjugates in Advanced HER2-low, Hormone Receptor-positive and Triple-negative Breast Cancer (SABCS 2024) - "Introduction: The emergence of sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) into the armamentarium has changed the treatment landscape for patients with HER2-low, hormone receptor (HR)-positive and triple-negative advanced breast cancer (TNBC). These data highlight specific challenges that HCPs are encountering with the integration of SG and T-DXd into clinical practice. The simulation of real-life clinical situations and participation in workshops with breast cancer experts helped to inform treatment decision-making and improved HCPs application of evidence-based medicine. These results show the impact of comprehensive educational models—developed from insights from learner surveys and expert perspectives on key data—to equip HCPs with the knowledge to ensure their practice aligns with current recommendations and increase confidence in making evidence-based treatment decisions for patients."

Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Sacituzumab govitecan in the treatment of triple-negative metastatic breast cancer. (PubMed, Recenti Prog Med) - "Since 2022, the ADC sacituzumab govitecan has been approved by the Italian Medicines Agency (Aifa) for the treatment of advanced/metastatic triple-negative breast cancer pretreated with at least two lines of systemic therapy, of which at least one for metastatic disease. In the collection of case reports, we delved into the available data on the efficacy profile and impact on quality of life of sacituzumab govitecan in several special populations of patients with triple-negative metastatic breast cancer."

Journal • Metastases • Review • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer (PRNewswire) - "MEDSIR...will participate in the prestigious San Antonio Breast Cancer Symposium 2024...The DEMETHER clinical trial...employs a dual-phase approach, beginning with an induction phase using trastuzumab deruxtecan (T-DXd), followed by a maintenance phase...Both the PHENOMENAL and TUXEDO-4 studies presented at SABCS are particularly relevant as they address a critical and historically underserved population: patients with metastatic breast cancer (MBC) and brain metastases (BMs)...The Phase III ADELA study, in collaboration with the MENARINI Group, explores new perspectives in the treatment of advanced ER+ and HER2-negative breast cancer....In addition to this study, MEDSIR is presenting the PRIMED trial, which evaluates the efficacy of prophylactic administration of granulocyte colony-stimulating factor (G-CSF) and loperamide during the initial treatment cycles of sacituzumab govitecan..."

Clinical data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Impact of Inflammatory Breast Cancer on Survival Outcomes in Metastatic Breast Cancer Patients Treated with Topoisomerase 1 based Antibody-Drug Conjugates (ADCs) (SABCS 2024) - "Background: Sacituzumab govitecan (SG) is an ADC targeting TROP2, coupled to SN-38, the active metabolite of irinotecan...Both groups had similar proportions receiving SG (49% for IBC patients vs. 50% for non-IBC patients) and T-DXd (51% vs. 50%)... Despite similar initial treatments and best response rates to ADCs, IBC patients exhibited inferior survival compared to non-IBC patients, with a median OS of 46.7 months versus 74.6 months. The PFS was similar between the two groups, indicating that IBC status did not significantly affect the time to disease progression. Further research is warranted to understand the higher lethality of IBC and explore optimal and tailored treatment strategies to improve survival rates for IBC patients."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Measurement of ADC Targets HER2 and TROP2 in Breast Cancer for Accuracy and Selection (SABCS 2024) - "We envision use of this assay to help sequence patients for Trastuzumab deruxtecan (T-DXd) and Sacituzumab govitecan (SG). The assay was sufficiently accurate and reproducible for validation in a CLIA lab. Studies are underway to determine the threshold for ADC response and to assess the value of this quantitative ranking assay to select between ADCs with the same indication."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • TACSTD2